- Oral presentation
- Open Access
Colchicine trial in PFAPA Syndrome and MEFV-negative patients
Pediatric Rheumatology volume 13, Article number: O5 (2015)
PFAPA Syndrome (Periodic Fever, Aphthous stomatitis, Pharingitis, and cervical Adenitis) is the most common periodic fever in childhood; the diagnosis is based on clinical criteria. Familiar Mediterranean Fever (FMF) is a monogenic autosomal recessive autoinflammatory disease, whose diagnosis is based on clinical elements, supported by MEFV genetic mutations. When there is only a mutation or no one, the patient undergoes a trial with colchicine for 4-6 months, and diagnosis is confirmed in case of clinical response and fever early recurrence after suspension. Current treatment of PFAPA is symptomatic. Febrile episodes show a rapid response to the administration of one or two doses of prednisone (1-2 mg/kg) or betamethasone (0.1-0.2 mg/kg). Total requirement of steroid increases over time, and the frequency of attacks worsens the quality of life of patients. In literature, the prophylaxis of PFAPA febrile attacks with colchicine (0.5-1 mg/day) has been tested only on a few patients, with controversial results.
Considering the similarities between FMF MEFV-negative patients (MEFVneg) and PFAPA patients, we aimed to demonstrate that colchicine is effective in PFAPA too: positive response was evaluated in terms of reduction in frequency >50% and severity of attacks >50%.
Materials and methods
We conducted a prospective cohort study (from September 2012, still ongoing), comparing two groups: 67 MEFVneg and 51 PFAPA patients. 36 of the latter group underwent colchicine trial, after obtaining informed consent.
We assessed the response of PFAPA patients to colchicine preventive treatment: good response was observed in 75% (27 patients of 36), and a non-response in 25% (9 pts). The effective treatment rate of MEFVneg is 100%, by definition. The average dose of colchicine administered in PFAPA was 1.14 mg/day, compared to MEFVneg (1.34 mg/day). The dose per kilogram of body weight is 0.020 mg/kg/day in both groups. We can state that the colchicine dose requirement in PFAPA coincides to the one of FMF patients.
Our study showed that colchicine regimen is effective in 75% of cases. Prophylaxis with colchicine should be offered to all PFAPA patients, instead of steroids or other symptomatic therapy (as paracetamol or ibuprofen), before the treatment with anti-IL1β biologic drugs, with considerable savings in pharmacoeconomics.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Kadhim, C., Maiolini, F., Cerrito, L. et al. Colchicine trial in PFAPA Syndrome and MEFV-negative patients. Pediatr Rheumatol 13 (Suppl 1), O5 (2015). https://doi.org/10.1186/1546-0096-13-S1-O5